–

9

7

7

,

9

7

6

t

fo

r

P

O

N

V

,

4

7

8

t

D

r

o

s

p

i

r

e

n

o

n

e

,

9

3

7

t

,

1

0

1

1

,

1

0

1

2

,

1

0

2

5

,

1

0

2

7

D

R

V

(

s

e

e

D

a

r

u

n

av

i

r

(

D

R

V)

)

D

T

a

P

(

s

e

e

D

i

p

h

t

h

e

ri

a

,

t

e

t

a

n

u

s

,

a

n

d

a

c

e

l

l

u

l

a

r

p

e

rt

u

s

s

i

s

(

D

T

a

P

)

)

D

T

I

C

(

s

e

e

D

a

c

a

rb

azi

n

e

(

D

T

I

C

)

)

D

u

l

a

g

l

u

t

i

d

e

,

1

1

2

6

–

1

1

2

7

,

1

1

3

9

D

u

l

e

r

a

(

s

e

e

M

o

m

e

t

a

s

o

n

e

/

fo

r

m

o

t

e

r

o

l

)

D

u

l

o

x

e

t

i

n

e

,

1

1

8

1

t

,

1

1

8

8

,

1

1

9

4

t

,

1

7

3

8

t

,

1

7

5

4

,

2

2

5

2

fo

r

d

e

p

r

e

s

s

iv

e

dis

o

r

d

e

r

s

,

1

8

1

9

t

,

1

8

2

0

t

,

1

8

2

1

t

fo

r

dia

b

e

t

e

s

,

1

1

4

5

,

2

2

2

6

t

fo

r

O

A

,

8

7

2

–

8

7

3

fo

r

s

e

r

o

t

o

nin

,

1

8

2

6

fo

r

s

tr

e

s

s

in

c

o

nt

in

e

n

c

e

,

2

2

5

2

D

u

ri

c

e

f

(

s

e

e

C

e

fa

d

r

o

x

i

l

)

D

u

t

a

s

t

e

ri

d

e

,

2

2

5

7

–

2

2

5

8

fo

r

B

P

H

,

2

2

5

7

–

2

2

5

8

fo

r

p

r

o

s

t

a

t

e

c

a

n

c

e

r

,

2

0

9

9

D

y

c

l

o

n

i

n

e

h

y

d

r

o

c

h

l

o

ri

d

e

,

1

9

7

4

D

y

m

i

s

t

a

(

s

e

e

az

e

l

a

s

t

i

n

e

H

C

l/

fl

u

t

i

c

a

s

o

n

e

p

r

o

p

i

o

n

a

t

e

)

D

y

n

a

b

a

c

(

s

e

e

D

i

ri

t

h

r

o

m

y

c

i

n

)

EE

c

a

m

s

u

l

e

,

8

4

9

t

,

8

5

2

E

c

h

i

n

a

c

e

a

,

1

6

6

1

E

c

h

i

n

o

c

a

n

d

i

n

s

,

1

5

6

9

,

1

6

2

5

,

1

6

2

9

t

,

1

6

3

1

,

1

6

3

2

,

1

6

3

6

,

1

6

4

0

,

1

6

4

3

E

c

h

o

t

h

i

o

p

h

a

t

e

i

o

d

i

d

e

,

1

1

5

2

–

1

1

5

3

E

c

o

n

az

o

l

e

,

1

6

2

4

t

E

c

s

t

a

s

y

(

s

e

e

3

,

4

-

m

e

t

h

yl

e

n

e

d

i

o

x

y

m

e

t

h

a

m

p

h

e

t

a

m

i

n

e

)

E

d

l

u

a

r

,

fo

r

t

r

e

a

t

m

e

n

t

o

f

i

n

s

o

m

n

i

a

,

1

7

6

7

t

E

d

o

x

a

b

a

n

,

1

3

0

7

t

fo

r

p

r

e

v

e

nt

io

n

o

f

s

tr

o

ke

,

1

7

8

,

3

1

7

–

3

1

8

E

fav

i

r

e

n

z

(

E

F

V)

,

9

4

2

t

fo

r

H

I

V

,

1

5

8

0

t

fo

r

H

I

V

in

la

b

o

r

,

9

9

6

E

ffe

x

o

r

(

s

e

e

Ve

n

l

a

fa

x

i

n

e

)

Effexor XR (see Venlafaxine)

EFV (see Efavirenz (EFV))

EGFR inhibitors (see Epidermal growth factor receptor (EGFR) inhibitors)

Eicosopentanoic acid (EPA), 125–126

Elbasvir, for HAV, 1688, 1689

Eldepryl (see Selegiline)

Elestat (see Epinastine)

Elestrin (see Estradiol gel; Estradiol topical emulsion/gel/solution)

Eletriptan, 1238t, 1239

Ellence (see Epirubicin)

Elotuzumab, 469t

Eloxatin (see Oxaliplatin)

Elspar (see Asparaginase)

Eluxadoline (Viberzi), 536

Emadine (see Emedastine)

Emedastine (Emadine), 439t

Emend (see Aprepitant; Fosaprepitant)

Emollients, for psoriasis, 835t

Empagliflozin, 1129–1130

Empiric antibiotics, 661

Empiric antifungal therapy, 1641

Emtricitabine (FTC), 1679

for HIV, 1577t

Enalaprilat (Vasotec IV), 171, 281–282, 281t, 335t, 2223

for hypertension, 153t, 344

Encainide, and PVC, 323

Enfuvirtide (T-20) Fuzeon, for HIV, 1580t

Engerix-B, 1355

Enjuvia (see Synthetic conjugated estrogens)

Enoxaparin, 177t, 188t, 189, 251, 252, 677–678

for ACS, 240t

LMWH, 656

and UFH, 254

Ensulizole, 849t

Entacapone, 1250t, 1251t, 1263–1264

adverse effects of, 1264

dose of, 1264

pharmacologic and pharmacokinetic properties of, 1263t

Entecavir, 1680

for HBV, 1678

Entocort EC, 523

Entresto (see Sacubitril/valsartan)

Enzalutamide, for prostate cancer, 2095

EPA (see Eicosopentanoic acid (EPA))

Epanova, 126

Ephedrine, in treatment of IDH, 657

Epidermal growth factor receptor (EGFR) inhibitors, 1978

Epinastine (Elestat), 439t

Epinephrine, 445, 446t, 2207t, 2208

for anaphylaxis, 687–688, 689t

for cardiogenic shock, 363t, 364

for cardiopulmonary arrest, 330–331

dose of, 330

for septic shock, 371

EpiPen 2-Pak, 446t

EpiPen Jr 2-Pak, 446t

Epipodophyllotoxins, 1981t

Epirubicin (Ellence), 469t, 1978–1979t, 1988

and hepatic dysfunction, 1996t

Eplerenone, 543

for hypertension, 140, 157

side effects of, 257

Epoetin alfa, 615

for anemia, 1942

Epoprostenol, 924

Epoxy resin, 822t

Eprosartan mesylate, for hypertension, 154t

EPT therapy (see Estrogen/progestogen (EPT) therapy)

Eptifibatide, for ACS, 237

Erbitux (see Cetuximab)

Ergocalciferol, 621

Ergot alkaloids

adverse effects of, 1239–1240

for migraine headache, 1239

Ergotamine, and lactation, 1003t

Eribulin, 469t

Erlotinib (Tarceva), 470t, 2064–2066

drug interaction with smoking, 1906t

Ertapenem (Invanz), 1326t

dosing of, 1337t

for gram-negative aerobes, 1327t

for UTI, 1497t

Erythrocin (see Erythromycin)

Erythromycin, 120t, 128, 828, 830, 942t, 1325t, 1371, 2163, 2163t

for acne, 828, 830

adverse effects of, 1332t

for aerobic gram-positive cocci, 1326t

and breast milk, 1001

for BV, 995

for Campylobacter infection, 1459

and dyspepsia, 487

for GBS infection, 995

for RMSF, 1725

for skin and soft tissue infections, 1547

for TBRF, 1722

Erythropoietic therapy, for anemia, 1942

Escitalopram (Lexapro), 1027t, 1036t, 1738, 1738t, 1748

for depressive disorders, 1819t, 1820t, 1821t

for diabetes, 2226t

for panic disorder, 1748

for PTSD, 1754

for SAD, 1752

for vasomotor symptoms, 1036t

ESHAP, for aggressive lymphomas, 2041–2042

Eslicarbazepine, 1279t, 1281

for seizures, 1286t

Esmolol (Brevibloc), 335t

for hypertension, 346

Esomeprazole, 228, 483t, 484, 485, 502, 1216t, 2163t

for end-of-life care, 95

for preventing SRMB, 515t

Estazolam, 1737t, 1767t

Esterified estrogen (Menest), 1033t

Estrace (see Estradiol cream)

Estradiol acetate tablet (Femtrace), 1033t

Estradiol acetate vaginal ring (Femring), 1033t

Estradiol cream (Estrace), 1033t, 2218

Estradiol gel (Divigel; Elestrin; Estrogel), 1033t

Estradiol hemihydrate tablets (Vagifem and Vagifem LD), 1033t

Estradiol hemihydrate tablets (Vagifem), 1033t

Estradiol ring (Estring), 1033t

Estradiol topical emulsion/gel/solution (Divigel, Elestrin, Estrogel, Estrasorb, Evamist), 1033t

Estradiol transdermal system, 1033t

Estramustine, 470t

p. 2300

p. 2301

Estrasorb (see Estradiol topical emulsion/gel/solution)

Estring (see Estradiol ring)

Estrogel (see Estradiol gel; Estradiol topical emulsion/gel/solution)

Estrogen/progestogen (EPT) therapy, 1031–1032t, 1035t, 1037

adverse effects of, 1035

Estrogens, 503t, 980, 2252–2253

androgen deprivation therapy, 2097

for stress incontinence, 2253

Estrostep, for acne, 829

Eszopiclone (Lunesta), 1767t, 1768–1770

Etanercept, 881, 895, 896t, 904

for PsA, 842–843

Ethacrynic acid, 580

for HF, 277

Ethambutol, 53

dosing of, 1337t

for MAC, 1619

optic neuritis and, 1437–1438

for tuberculosis, 1429t, 1433

Ethanol, 1891

for diabetes, 1146

Ethinyl estradiol

for endometriosis, 1019

OC formulations, 1016

Ethionamide, for tuberculosis, 1430t

Ethosuximide, 1279t

for absence seizures, 1290–1291, 1291t

Ethylenediamine, 822t

Ethynodiol diacetate, 936–937t

Etidronate, for hypercalcemia, 589t, 590

Etodolac, 870t, 888t

Etomidate, 2198

for pediatric intubation, 2200t

Etoposide, 469t, 470t, 1978–1979t, 1981t, 1987, 1990, 1996t, 2003–2005, 2018, 2040t

for aggressive lymphomas, 2042

for blood progenitor cell rescue, 2005

and hepatic dysfunction, 1996t

hypotensive reactions of, 2005

for NSCLC, 2062t

peripheral nerve toxicity of, 1986

for rhabdomyosarcoma, 2010, 2011

for SCLC, 2068–2069, 2068t

Etoricoxib, 1044

Etravirine (ETV), for HIV, 1580t

Etretinate, teratogenic effects, 973t

Eucalyptus, 1721

Evamist (see Estradiol topical emulsion/gel/solution)

Everolimus, 120t, 128, 226, 470t, 722

Evolocumab, 129–131

Exenatide, for type 2 diabetes, 1126–1127, 1135, 1136–1138

Ezetimibe, 130, 1306

adverse effects, 122

clinical pearls, 122

drug interactions, 122

efficacy, 121–122

mechanism of action, 121, 121f

pharmacokinetics/pharmacodynamics, 122

place in therapy, 122

Ezogabine, 1279t, 1281

for seizures, 1285t

F

Factive (see Gemifloxacin)

Famciclovir (FCV), 1648t

adverse effects, 1647t

for genital herpes, 1529–1530, 1530t

for herpes zoster infection, 1652

pharmacokinetics of, 1653t

Famotidine, 977, 1216t, 2163t

H2RA, 483t, 484

for preventing SRMB, 515t

Fampridine, 1224

Fanapt (see Iloperidone)

Fansidar (see Sulfadoxine)

Fat-soluble vitamins, 453

for patients with CF, 457t

FCV (see Famciclovir (FCV))

Febuxostat, 916

drug interactions, 918t

Felbamate, 942t, 1279t, 1281

Felodipine, for chronic stable angina pectoris, 214

Femring (see Estradiol acetate vaginal ring)

Femtrace (see Estradiol acetate tablet)

Fennel, for dysmenorrhea, 1015

Fenofibrate, 124, 124t, 918

Fenofibric acids, 124, 124t

Fenoldopam (Corlopam), 335t

for BP, 341

for hypertensive crisis, 342

for hypertensive emergencies, 342

Fenoprofen, 870t, 888t

Fentanyl, 1178, 1187t

dosage of, 1199t, 1201t

for opioid withdrawalsyndrome, 1880

for pediatric intubation, 2199t

Feraheme (see Ferumoxytol)

Ferric carboxymaltose, for anemia, 1931

Ferric citrate, 620t

Ferric gluconate, for anemia, 1931, 1932, 1933

Ferritin, for anemia, 1930

Ferrous fumarate, for anemia, 1930

Ferrous gluconate, for anemia, 1930

Ferrous sulphate, 1261t

for anemia, 1930

Ferumoxytol, 614, 696

for anemia, 1931, 1932, 1933

Fesoterodine, 2251

Fexofenadine (Allegra), 128, 433t

for rhinitis, 437

Fibric acid, 124t, 914t

adverse effects, 124

clinical pearls, 125

drug interactions, 125

efficacy, 123–124

mechanism of action, 123, 123f

pharmacokinetics/pharmacodynamics, 124

place in therapy, 124–125

Fibrinolytic therapy, 191–192

Fibronectin, 991

Fidaxomicin (Dificid), 1325t

15-methyl prostaglandin F2

α

-tromethamine, 997–998

Finasteride, 2257

for BPH, 2257

for hirsutism, 1012–1013

for prostate cancer, 2099

Fingolimod, 1222, 1228–1229, 1229t

5-α-reductase inhibitors, 2098

5-aminosalicylic acid (5-ASA), 520

for Crohn’s disease, 529

5-flucytosine (5-FC), 1400, 1624

amphotericin B and, 1400

5-fluorouracil, 469t, 1614

5-HT3

antagonists, for CINV, 471, 472t

Flagyl (see Metronidazole)

Flecainide, 1906t

for AF, 315

for HF, 275

and PVC, 323

for WPW, 320

FlexPen, 1086

FlexTouch, 1086, 1087

Flonase Sensimist (see Fluticasone furoate)

Floxin (see Ofloxacin)

Floxuridine, 469t

Fluconazole (Diflucan), 120t, 128, 942t, 1614–1616, 1624, 1624t, 1625, 1626t

a

dv

e

r

s

e

e

ffe

c

t

s

o

f,

1

3

3

4

t

fo

r

C

A

P

D

-

a

s

s

o

c

ia

t

e

d

p

e

r

it

o

nit

is

,

1

4

7

6

t

fo

r

c

hr

o

nic

p

ulmo

n

a

r

y

b

la

s

t

o

my

c

o

s

is

,

1

6

3

7

C

N

S

p

e

n

e

tr

a

t

io

n

o

f,

1

6

4

0

c

r

yp

t

o

c

o

c

c

a

l

dis

e

a

s

e

,

1

6

4

3

do

s

in

g

o

f,

1

3

3

7

t

fo

r

fun

g

a

l

e

n

do

c

a

r

dit

is

,

1

4

0

0

fo

r

fun

g

a

l

in

fe

c

t

io

n

,

1

4

7

9

fo

r

s

e

p

s

is

,

2

1

8

6

t

fo

r

V

V

C

,

1

5

2

5

t

,

1

5

2

6

F

l

u

c

yt

o

s

i

n

e

,

1

6

1

4

–

1

6

1

5

,

1

6

2

5

a

dv

e

r

s

e

e

ffe

c

t

s

o

f,

1

3

3

4

t

,

1

6

4

3

a

n

d

c

r

e

a

t

inin

e

c

le

a

r

a

n

c

e

,

1

6

4

3

c

r

yp

t

o

c

o

c

c

a

l

dis

e

a

s

e

,

1

6

4

3

do

s

in

g

o

f,

1

3

3

7

t

a

n

d

GI

dis

tr

e

s

s

,

1

6

4

3

fo

r

O

I

s

,

1

5

9

8

r

e

n

a

l

e

x

c

r

e

t

io

n

o

f,

1

6

4

3

r

is

k

fa

c

t

o

r

C

,

1

6

3

7

F

l

u

d

a

r

a

b

i

n

e

,

4

6

9

t

,

4

7

0

t

,

1

9

8

5

–

1

9

8

6

,

1

9

9

1

t

,

1

9

9

5

t

fo

r

C

L

L

,

2

0

3

3

e

n

c

e

p

h

a

lop

a

th

ic

t

o

x

ic

ity

o

f,

1

9

8

5

n

e

ur

o

t

o

x

ic

ity

o

f,

1

9

8

5

t

F

l

u

d

r

o

c

o

rt

i

s

o

n

e

,

i

n

t

r

e

a

t

m

e

n

t

o

f

I

D

H

,

6

5

7

F

l

u

m

a

d

i

n

e

(

s

e

e

R

i

m

a

n

t

a

d

i

n

e

)

F

l

u

m

az

e

n

i

l

,

1

7

4

4

,

1

7

4

6

h

e

p

a

t

ic

e

n

c

e

p

h

a

lop

a

thy

,

5

5

3

fo

r

p

e

dia

tr

ic

intub

a

t

io

n

,

2

2

0

0

t

F

l

u

M

i

s

t

,

1

3

6

1

in

flu

e

nz

a

v

a

c

c

in

e

,

1

6

5

7

F

l

u

n

i

s

o

l

i

d

e

,

4

4

1

t

fo

r

a

lle

r

g

ic

r

h

init

is

,

4

4

2

fo

r

B

P

D

,

2

1

7

6

F

l

u

o

r

o

c

yt

o

s

i

n

e

,

1

6

2

4

t

F

l

u

o

r

o

m

e

t

h

o

l

o

n

e

a

c

e

t

a

t

e

,

1

1

6

6

p. 2

3

0

1

p. 2

3

0

2

F

l

u

o

r

o

p

y

ri

m

i

d

i

n

e

,

fo

r

c

o

l

o

n

c

a

n

c

e

r

,

2

0

7

3

F

l

u

o

r

o

q

u

i

n

o

l

o

n

e

s

,

4

6

0

,

4

8

4

,

1

3

7

1

,

1

5

4

9

,

1

7

2

0

a

n

d

a

nt

a

c

id

s

,

4

1

fo

r

b

a

c

t

e

r

ia

l

p

r

o

s

t

a

t

it

is

,

1

5

0

4

fo

r

C

a

mp

y

lo

b

a

c

t

e

r

in

fe

c

t

io

n

,

1

4

5

9

fo

r

C

A

P

,

1

4

1

3

fo

r

C

A

P

D

-

a

s

s

o

c

ia

t

e

d

p

e

r

it

o

nit

is

,

1

4

7

5

fo

r

C

O

P

D

,

4

2

4

fo

r

g

o

n

o

r

r

h

e

a

,

1

5

0

9

fo

r

in

fe

c

t

io

u

s

dia

r

r

h

e

a

,

1

4

4

9

fo

r

M

A

C

,

1

6

1

9

fo

r

n

o

ntyp

h

o

id

a

l

s

a

lmo

n

e

llo

s

is

,

1

4

5

3

–

1

4

5

4

fo

r

s

kin

a

n

d

s

o

ft

t

is

s

u

e

in

fe

c

t

io

n

s

,

1

5

4

9

fo

r

s

ur

g

ic

a

l

p

r

o

c

e

dur

e

s

,

1

3

4

5

t

fo

r

T

B

,

1

4

3

1

for UTI, 1491, 1493

for UTI in pediatric patients, 1497

Fluorouracil, 1972, 1977, 1978, 1978t, 1990

for adverse effects, 2076–2077, 2080

and cerebellar dysfunction, 1985

for colon cancer, 2073

encephalopathic toxicity of, 1985

and hepatic dysfunction, 1996t

neurotoxicity of, 1985t

Fluoxetine (Prozac or Sarafem), 1027t, 1738, 1738t, 1748, 1778

for bipolar depression, 1847

for depression, 2245

for depressive disorders, 1819t, 1820t, 1821t

for diabetes, 2226t

for OCD, 1760

for panic disorder, 1748

for PTSD, 1754

for Raynaud’s disease, 171

and sleep, 1774

for vasomotor symptoms, 1036t

Fluphenazine, 1789t, 1797t, 1799t

decanoate, 1795t

for schizophrenia, 1793t

Flurazepam, 1768

and sleep, 1772

for treatment of insomnia, 1767t

Flurbiprofen, 870t, 888t

Flutamide, for prostate cancer, 2093

Fluticasone

for BPD, 2176